Stay updated with breaking news from Foundation Synchrony. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The company said it plans to focus on the development of its Zygel CBD gel on autism spectrum disorder and 22q11.2 deletion syndrome along...
(1) -First precision therapeutic to be investigated in a biologically defined ASD subpopulation: ASD-Phen1 discovered and clinically validated by STALICLA- -STP1 could provide a new therapeutic option for as many as 20% of patients with non-monogenetic causes of ASD- STALICLA SA, today announced first patient enrolled in its Phase 1b clinical trial with STP1, a first in class precision medicine for patients within the autism spectrum disorder (ASD) Phenotype 1 subgroup (ASD-Phen1), a novel biological subgroup identified by STALICLA's proprietary discovery platform. STP1 is a novel combina...